{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4","value":"107"},{"groupId":"OG001","spread":"1.3","value":"107"},{"groupId":"OG002","spread":"1.3","value":"105"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"219"},{"groupId":"OG002","value":"233"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"113"},{"groupId":"OG001","spread":"1.7","value":"115"},{"groupId":"OG002","spread":"1.6","value":"113"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"title":"1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.8","value":"114"},{"groupId":"OG001","spread":"1.7","value":"115"},{"groupId":"OG002","spread":"1.7","value":"115"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"139"},{"groupId":"OG002","value":"128"}],"units":"Participants"}],"title":"2 Years"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0","value":"115"},{"groupId":"OG001","spread":"2.1","value":"114"},{"groupId":"OG002","spread":"2.2","value":"115"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"96"}],"units":"Participants"}],"title":"3 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"254"},{"groupId":"OG002","value":"257"}],"units":"Participants"}],"description":"The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has 37 questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.","dispersionType":"Standard Error","groups":[{"description":"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG000","title":"Tandem Auto Transplant"},{"description":"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance\n\nlenalidomide, bortezomib and dexamethasone: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG001","title":"RVD Consolidation"},{"description":"Initial autologous transplant followed by lenalidomide maintenance\n\nLenalidomide: All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.","id":"OG002","title":"Lenalidomide Maintenance"}],"paramType":"MEAN","populationDescription":"Outcomes are analyzed from participants that were alive, progression-free, and completed assessments.","reportingStatus":"POSTED","timeFrame":"Up to 3 years post-randomization","title":"FACT-BMT Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}